Page 96 - உணர்ச்சி பல்கலைக்கழகம் இல் அட்லாண்டா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Minimal residual disease (MRD) negativity and its duration led to significantly better progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma, new analyses of two randomized trials showed. MRD-negative rates increased significantly with the addition of daratumumab (Darzalex) to standard therapy, from 6.7% with lenalidomide (Revlimid) and dexamethasone (Rd) to 32.5% with the addition of the anti-CD38 antibody (DRd) and from 1.6% with bortezomib (Velcade)-dexamethasone (Vd) to 15.1% with daratumumab-VD (DVd). The proportion of patients who had MRD-negative status for 6 months or longer increased about 10-fold when daratumumab was added to Rd or Vd. Progression-free survival (PFS) increased with MRD-negativity and its duration, Hervé Avet-Loiseau, MD, of University Cancer Institute-Oncopole in Toulouse, France, and co-authors reported in the

Charles bankheadEmory university in atlantaInternational myeloma working groupWinship cancer instituteUniversity cancer instituteUniversity cancer institute oncopoleSagar lonialEmory universityMedpage todayMultiple myelomaMass of body structureNeoplastic diseaseசார்லஸ் வங்கித் தலைஉணர்ச்சி பல்கலைக்கழகம் இல் அட்லாண்டாசர்வதேச மைலோமா வேலை குழுவெற்றி புற்றுநோய் நிறுவனம்